Inhaled nitric oxide in fibrotic and advanced interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials
PLOS One · 22.06.2026 · 21 (6) · e0351862
DOI: 10.1371/journal.pone.0351862 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PLOS One, online erschienen am 22.06.2026. Verfasst von Shun Nakahara und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America. Hauptthemen laut MEDLINE: Nitric Oxide, Lung Diseases, Interstitial. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Interstitial lung disease (ILD) can lead to pulmonary hypertension (PH), contributing to reduced exercise capacity in patients with ILD. Inhaled nitric oxide (iNO) reduces pulmonary artery pressure and pulmonary vascular resistance and may improve exercise capacity in this population; however, the available evidence remains limited. Therefore, we conducted a systematic review and meta-analysis to compare the efficacy and safety of iNO versus placebo in patients with ILD.
Methods
We systematically searched PubMed, Embase, Cochrane databases, and ClinicalTrials.gov for randomized controlled trials (RCTs) comparing iNO with placebo in patients with ILD. The primary endpoint was 6-minute walk distance (6MWD). Secondary endpoint was moderate-to-vigorous physical activity (MVPA). Safety endpoint was any adverse events. Continuous endpoints were reported using mean differences (MDs) or standardized mean differences (SMDs), and binary endpoints were reported using risk ratios (RRs), all with 95% confidence intervals (CIs).
Results
Four RCTs, including one crossover trial, enrolling 274 patients were analyzed. Of these, 172 received iNO. The median follow-up period was 12 weeks. In the pooled analyses, iNO likely results in little to no difference in 6MWD compared with placebo (MD 1.83m; 95% CI −12.98 to 16.64; p = 0.81), and may result in little to no difference in any adverse events (RR 1.12; 95% CI 0.97 to 1.30; p = 0.12) and MVPA (SMD 0.32; 95% CI −0.93 to 1.56; p = 0.39).
Conclusion
INO did not demonstrate improvements in 6MWD or MVPA. These findings do not support routine use of iNO in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
- Pulmonary and Critical Care Division, Queen's University Medical Group, Honolulu, Hawaii, United States of America.
ORCID-Profile: Shun Nakahara
Zitieren
APA
Nakahara, S., Hirao, Y., Fujiuchi, B., & Matsuda, B. (2026). Inhaled nitric oxide in fibrotic and advanced interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials. PLOS One, 21(6), e0351862. https://doi.org/10.1371/journal.pone.0351862
Vancouver
Nakahara S, Hirao Y, Fujiuchi B, Matsuda B. Inhaled nitric oxide in fibrotic and advanced interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials. PLOS One. 2026;21(6):e0351862. doi:10.1371/journal.pone.0351862
BibTeX
@article{Nakahara2026,
author = {Nakahara, Shun and Hirao, Yusuke and Fujiuchi, Bradley and Matsuda, Brent},
title = {Inhaled nitric oxide in fibrotic and advanced interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {6},
pages = {e0351862},
doi = {10.1371/journal.pone.0351862}
}
EUVIMED